


# Application of cardiac surgery techniques to improve the results of cardiopulmonary resuscitation after cardiac arrest: Controlled automated reperfusion of the whole body

Friedhelm Beyersdorf, MD, Georg Trummer, MD, Christoph Benk, PhD, and Jan-Steffen Pooth, MD



CARL components.

### CENTRAL MESSAGE

The application of cardiac surgical techniques to reduce ischemia-reperfusion injury to the whole body can be used to improve the results of cardiopulmonary resuscitation after cardiac arrest.

See Commentary on page XXX.

Until now, the overall results (survival and neurologic outcome) of cardiopulmonary resuscitation (CPR) after cardiac arrest (CA) have been quite dismal. They have improved when compared with the outcome over the past number of decades but are still far from ideal. This is true for both out-of-hospital cardiac arrest<sup>1,2</sup> and in-hospital cardiac arrest.<sup>3</sup> Survival after out-of-hospital cardiac arrest is reported to be in the range of 8% to 10%<sup>2</sup> with neurologic damage found in many of the survivors.<sup>4</sup> Nevertheless, all major efforts in the field of resuscitation (including CPR by laymen and professionals, improved alarm systems, and better medications) are more than valued and have resulted in some very favorable outcomes.

The pathophysiologic mechanism of injury after CA is ischemia reperfusion, not only in vital organs but also to the whole body (Figure 1). After ischemia induced by CA, low-flow reperfusion is usually established during the first phase by CPR (basic life support and advanced life support). CPR may result in the return of spontaneous circulation or (in selected cases) in the use of extracorporeal circulation. Even if return of spontaneous circulation could be established, intermittent phases of additional CA may occur.

Therefore, the reasons for the poor results of CPR after CA can be classified as:

- Critical underlying disease (eg, left ventricle rupture, free ruptured thoracic aortic aneurysms, and massive cerebral bleeding),
- Multimorbidities (eg, end-stage lung disease, chronic renal/liver failure, frailty, insulin-dependent diabetes, severe neurologic disorders, and end-stage cancer), and
- Acute multiorgan damage after ischemia-reperfusion injury.

To minimize this whole-body ischemia-reperfusion injury, we introduced the concept of controlled automated reperfusion of the whole body (CARL), which is based on cardiac surgical techniques, developed over the past 20 to 30 years (Figure 1, C). CARL was developed to reduce/avoid ischemia-reperfusion injury after CA but it has not been found to be successful in critical diseases or in multimorbid patients.

Intensive work in this field has resulted in previously unknown success in myocardial protection as well as organ protection in general.<sup>5-7</sup> Indeed, over the past decade a new


From the Department of Cardiovascular Surgery, University Hospital Freiburg, and Medical Faculty of the Albert-Ludwigs-University Freiburg, Freiburg, Germany.

Received for publication July 31, 2021; accepted for publication Oct 13, 2021.

Address for reprints: Friedhelm Beyersdorf, MD, Department of Cardiovascular Surgery, University Hospital Freiburg, Hugstetterstr 55, D-79106 Freiburg, Germany (E-mail: [friedhelm.beyersdorf@uniklinik-freiburg.de](mailto:friedhelm.beyersdorf@uniklinik-freiburg.de)).

JTCVS Open 2021; ■:1-6  
2666-2736

Copyright © 2021 The Authors. Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).  
<https://doi.org/10.1016/j.xjon.2021.10.006>

127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248

**FIGURE 1.** Development of ischemia reperfusion injury in treatments of cardiac arrest. Cardiac arrest results in whole body ischemia. A, Cardiopulmonary resuscitation (CPR) may restore minimal blood flow by chest compressions and few or no ventilation (minimal uncontrolled reperfusion; ie, unmodified blood, low flow, low pressure, minimal, or no oxygen). B, Extracorporeal CPR (eCPR) has shown beneficial effects but represents an undefined therapy approach. C, Controlled automated reperfusion of the whole body (CARL) reduces reperfusion injury by control and modification of more than 10 blood parameters and control and modification of specific reperfusion parameters (for details see Table 1).

field of research in applying innovative cardiac surgical techniques to the field of CA and CPR<sup>8-14</sup> has emerged.

The aim of this Invited Expert Opinion article is to review the pathophysiology of ischemia–reperfusion injury after CA, the scientific background and clinical development for CARL, and the latest experimental data. The CARL concept is also addressed in Video 1.

## SCIENTIFIC BACKGROUND

Our group in Freiburg, in cooperation with our colleagues from Yale University and the Max-Planck-Institute in Cologne, Germany, has recently published a review in *Nature Reviews Neuroscience* describing the scientific background of the ischemia tolerance of the brain as the most ischemia-sensible organ and opportunities to treat ischemia reperfusion injury (IRI) by modifications and control of the initial reperfusion phase.<sup>14</sup> Previous reports have already shown that the ischemic tolerance, even of the brain, is substantially prolonged if appropriate reperfusion conditions are applied.<sup>11,15,16</sup>


After more than 15 to 20 years of research, our group has developed a technique called CARL (Figure 2), which

enables users to clinically apply many of the important basic science principles recently outlined in detail.<sup>14</sup> The reperfusion parameters, which are controlled by our CARL technique, are summarized in Table 1.

In addition to the development of the scientific background for this new approach,<sup>9-14</sup> innovative



**VIDEO 1.** Professor Beyersdorf explains the rationale of controlled automated reperfusion of the whole body (CARL). Video available at: [https://www.jtcvs.org/article/S2666-2736\(21\)00356-9/fulltext](https://www.jtcvs.org/article/S2666-2736(21)00356-9/fulltext).



**FIGURE 2.** A, Schematic drawing of the controlled automated reperfusion of the whole body (CARL) set up. B, Picture of CARL controller, CARL oxygenation controller (CARL MOX), and CARL cooler. BGA, ■ ■ ■.

technical developments have evolved and have resulted in a new, portable device (the CARL Controller), which allows the principles of the CARL therapy to be applied (Table 1) in and out of the hospital, including controlled oxygenation (the CARL MOX) and immediate cooling of the patient (the CARL Cooler) (Figure 2). This technology can be used routinely inside the hospital, but is also intended to be used outside the hospital in selected cases. The out-of-hospital use is already being practiced in some centers in Germany.

To improve the results of CPR after CA, the use of extracorporeal circulation systems was introduced by several groups around the world.<sup>50-53</sup> Although its superiority over standard CPR techniques has not been established, there are several indications showing the beneficial effects in selected patients. Nevertheless,

extracorporeal CPR does not address the consequences of ischemia–reperfusion injury directly (Figure 1). Therefore, based on the current pathophysiologic knowledge for brain viability after ischemia<sup>14</sup> the CARL therapy has been developed to control a number of different aspects of IRI, which are outlined in Tables 1 and 2.

### PRELIMINARY CLINICAL DATA

The resulting clinical data of preliminary pilot studies using this new technique are very promising.<sup>54-56</sup> In the preliminary clinical study, 7 out of 14 surviving patients regained full consciousness, whereas 6 of these 7 were assigned to cerebral performance class 1.<sup>55</sup>

However, before any meaningful conclusions can be drawn, the ongoing multicenter, European clinical study (postmarket clinical follow-up) (DRKS00018967),

**TABLE 1. Rationale for controlled automated reperfusion of the whole body (CARL)**

Overall	Parameter	Rationale	Publications
Composition of reperfusate	Calcium	Lowering serum calcium to prevent cellular calcium uptake in first minutes of reperfusion to avoid additional cell damage	Refs <sup>17-23</sup>
	Sodium	Avoid excessive alterations of serum sodium levels with respect to cerebral volume displacements and subsequent cerebral edema	Refs <sup>17,24,25</sup>
	Potassium	Secondary cardioplegia; that is, convert ventricular flutter/fibrillation into asystole with subsequent minimized oxygen demand of the myocardium. Secondary cardioplegia using elevated potassium levels is only applicable when stable circulatory support is provided by extracorporeal circulation	Refs <sup>26</sup>
	Magnesium	Increase magnesium to support membrane stabilization	Ref <sup>27</sup>
	Viscosity	Lowering viscosity to improve perfusion by reducing the no-reflow-phenomenon	Refs <sup>28</sup>
	Hemodilution	Improving perfusion by reducing the no-reflow-phenomenon	Refs <sup>28,29</sup>
	Osmolality	Increase serum osmolality to limit cerebral edema and decrease vasopressor requirements	Refs <sup>30,31</sup>
	Colloid osmotic pressure	Increase colloid osmotic pressure to limit cerebral edema and decrease vasopressor requirements	Refs <sup>30,31</sup>
	Oxygen	Lowering oxygen to limit generation of oxygen free radicals	Refs <sup>23,32</sup>
	Carbon dioxide	Permission of temporary elevated carbon dioxide levels to support pH-stat strategy	Ref <sup>33</sup>
	pH	pH-stat strategy to lower cellular metabolism during first 30 min of reperfusion until substrates are replenished	Ref <sup>33</sup>
	Lidocaine	Addition of lidocaine for rhythm conversion or stabilization	Refs <sup>27,34,35</sup>
	Anticoagulation	Avoid clotting and improve microcirculatory perfusion	Ref <sup>36</sup>
Free radical scavengers	Addition of free radical scavengers to limit reactive oxygen species	Refs <sup>23,32,37-39</sup>	
Conditions of reperfusion	Flow	High Flow to enhance hemodynamic power to reopen capillary flow areas and counteract the no-reflow-phenomenon especially in the brain	Refs <sup>40,41</sup>
	Temperature	Immediate mild hypothermia to lower cellular oxygen demand	Refs <sup>33,42-49</sup>
	Pressure	High pressure to reduce the no-reflow-phenomenon	Refs <sup>28,40,41</sup>
	Pulsatility	Enhanced hemodynamic power to reopen capillary flow areas and counteract the no-reflow-phenomenon, especially in the brain	Ref <sup>40</sup>

Ref, Reference.

sponsored by a European Union grant (Horizon 2020) has to be finalized. The enrollment was unfortunately delayed by the COVID-19 pandemic and is now expected to be closed in the coming 12 to 18 months.

**TABLE 2. Comparison of diagnostic and therapeutic options of cardiopulmonary resuscitation (CPR), extracorporeal CPR (eCPR), and controlled automated reperfusion of the whole body (CARL) after out-of-hospital cardiac arrest**

Option	CPR	eCPR	CARL
Venoarterial perfusion and oxygenation	(✓)	✓	✓
High arterial perfusion pressure	–	–	✓
Pulsatile arterial blood flow	–	–	✓
High arterial blood flow	–	–	✓
Immediate hypothermia	–	–	✓
Continuous BGA (venous and arterial)	–	–	✓
Controlled oxygenation	–	–	✓
Hypocalcemia	–	–	✓
Hyperkalemia	–	–	✓
Hyperosmolality	–	–	✓

✓, Available/possible; (✓), partially available/possible; –, not available/not possible, BGA, ■■■.

## CONCLUSIONS

The application of cardiac surgical techniques and innovative approaches to reduce IRI after CA has shown superior outcomes in different experimental models. Extensive basic research has been performed to develop new treatment modalities and to improve results after CA. This knowledge has led to innovative technologies that enable the application of these novel therapeutic principles in clinical practice. Preliminary clinical data have shown very promising results.

## Conflict of Interest Statement

Dr Beyersdorf is founder and shareholder of Resuscitec GmbH, a start-up company of the University Hospital Freiburg. Drs Trummer and Benk are part-time employees and shareholders of Resuscitec GmbH. Dr Pooth is a part-time employee of Resuscitec GmbH.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

## References

1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics—2020 update: a report from the American Heart Association. *Circulation*. 2020;141:e139-e596.
2. Bougouin W, Dumas F, Lamhaut L, Marijon E, Carli P, Combes A, et al. Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest: a registry study. *Eur Heart J*. 2020;41:1961-71.
3. Perkins GD, Gräsner J-T, Semeraro F, Olasveengen T, Soar J, Lott C, et al. European Resuscitation Council Guidelines 2021: executive summary. *Resuscitation*. 2021;161:1-60.
4. Moulart VRMP, Verbunt JA, van Heugten CM, Wade DT. Cognitive impairments in survivors of out-of-hospital cardiac arrest: a systematic review. *Resuscitation*. 2009;80:297-305.
5. Beyersdorf F, Kirsh M, Buckberg GD, Allen BS. Warm glutamate/aspartate-enriched blood cardioplegic solution for perioperative sudden death. *J Thorac Cardiovasc Surg*. 1992;104:1141-7.
6. Beyersdorf F. The use of controlled reperfusion strategies in cardiac surgery to minimize ischaemia/reperfusion damage. *Cardiovasc Res*. 2009;83:262-8.
7. Allen BS, Veluz JS, Buckberg GD, Aeberhard E, Ignarro LJ. Deep hypothermic circulatory arrest and global reperfusion injury: avoidance by making a pump prime reperfusate—a new concept. *J Thorac Cardiovasc Surg*. 2003;125:625-32.
8. Trummer G, Foerster K, Buckberg GD, Benk C, Heilmann C, Mader I, et al. Successful resuscitation after prolonged periods of cardiac arrest: a new field in cardiac surgery. *J Thorac Cardiovasc Surg*. 2010;139:1325-32.
9. Foerster K, D'Inka M, Beyersdorf F, Benk C, Nguyen-Thanh T, Mader I, et al. Prolonged cardiac arrest and resuscitation by extracorporeal life support: favourable outcome without preceding anticoagulation in an experimental setting. *Perfusion*. 2013;28:520-8.
10. Trummer G, Foerster K, Buckberg G, Benk C, Mader I, Heilmann C, et al. Superior neurologic recovery after 15 minutes of normothermic cardiac arrest using an extracorporeal life support system for optimized blood pressure and flow. *Perfusion*. 2014;29:130-8.
11. Taunyane IC, Benk C, Beyersdorf F, Foerster K, Cristina Schmitz H, Wittmann K, et al. Preserved brain morphology after controlled automated reperfusion of the whole body following normothermic circulatory arrest time of up to 20 minutes. *Eur J Cardiothorac Surg*. 2016;50:1025-34.
12. Kreibich M, Trummer G, Beyersdorf F, Scherer C, Förster K, Taunyane I, et al. Improved outcome in an animal model of prolonged cardiac arrest through pulsatile high pressure controlled automated reperfusion of the whole body: animal model of prolonged CA through pulsatile high pressure CARL. *Artif Organs*. 2018;42:992-1000.
13. Foerster K, Benk C, Beyersdorf F, Cristina Schmitz H, Wittmann K, Taunyane I, et al. Twenty minutes of normothermic cardiac arrest in a pig model: the role of short-term hypothermia for neurological outcome. *Perfusion*. 2018;33:270-7.
14. Daniele SG, Trummer G, Hossmann KA, Vrselja Z, Benk C, Gobeke KT, et al. Brain vulnerability and viability after ischaemia. *Nat Rev Neurosci*. 2021;22:553-72.
15. Hossmann K-A, Schmidt-Kastner R, Grosse Ophoff B. Recovery of integrative central nervous function after one hour global cerebro-circulatory arrest in normothermic cat. *J Neurol Sci*. 1987;77:305-20.
16. Vrselja Z, Daniele SG, Silbereis J, Talpo F, Morozov YM, Sousa AMM, et al. Restoration of brain circulation and cellular functions hours post-mortem. *Nature*. 2019;568:336-43.
17. Blaustein MP, Lederer WJ. Sodium/calcium exchange: its physiological implications. *Physiol Rev*. 1999;79:763-854.
18. Choi DW. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. *Trends Neurosci*. 1988;11:465-9.
19. Taunyane IC, et al. Preserved brain morphology after controlled automated reperfusion of the whole body following normothermic circulatory arrest time of up to 20 minutes. *Eur J Cardiothorac Surg*. 2016;50:1025-34.
20. Kristián T, Siesjö BK. Calcium in ischemic cell death. *Stroke*. 1998;29:705-18.
21. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. *Nat Rev Mol Cell Biol*. 2003;4:552-65.
22. Xiong Z-G, et al. Neuroprotection in ischemia. *Cell*. 2004;118:687-98.
23. Starkov AA, Chinopoulos C, Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. *Cell Calcium*. 2004;36:257-64.
24. Jiang C, Agulian S, Haddad GG. Cl<sup>-</sup> and Na<sup>+</sup> homeostasis during anoxia in rat hypoglossal neurons: intracellular and extracellular in vitro studies. *J Physiol*. 1992;448:697-708.
25. Xie Y, Dengler K, Zacharias E, Wilffert B, Tegtmeyer F. Effects of the sodium channel blocker tetrodotoxin (TTX) on cellular ion homeostasis in rat brain subjected to complete ischemia. *Brain Res*. 1994;652:216-24.
26. Liakopoulos OJ, et al. Resuscitation after prolonged cardiac arrest: role of cardiopulmonary bypass and systemic hyperkalemia. *Ann Thorac Surg*. 2010;89:1972-9.
27. Letson HL, Granfeldt A, Jensen TH, Mattson TH, Dobson GP. Adenosine, lidocaine, and magnesium support a high flow, hypotensive, vasodilatory state with improved oxygen delivery and cerebral protection in a pig model of noncompressible hemorrhage. *J Surg Res*. 2020;253:127-38.
28. Fischer EG, Ames A. Studies on mechanisms of impairment of cerebral circulation following ischemia: effect of hemodilution and perfusion pressure. *Stroke*. 1972;3:538-42.
29. Olsson Y, Hossmann K-A. The effect of intravascular saline perfusion on the sequelae of transient cerebral ischemia: light and electron microscopical observations. *Acta Neuropathol (Berlin)*. 1971;17:68-79.
30. Jungner M, Grände P-O, Mattiasson G, Bentzer P. Effects on brain edema of crystalloid and albumin fluid resuscitation after brain trauma and hemorrhage in the rat. *Anesthesiology*. 2010;12:1194-203.
31. Golab HD, et al. Relevance of colloid oncotic pressure regulation during neonatal and infant cardiopulmonary bypass: a prospective randomized study. *Eur J Cardiothorac Surg*. 2011;39:886-91.
32. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. *J Cereb Blood Flow Metab*. 2001;21:2-14.
33. Yenari M, Kitagawa K, Lyden P, Perez-Pinzon M. Metabolic downregulation: a key to successful neuroprotection? *Stroke*. 2008;39:2910-7.
34. Bergey JL, Nocella K, McCallum JD. Acute coronary artery occlusion-reperfusion-induced arrhythmias in rats, dogs and pigs: antiarrhythmic evaluation of quinidine, procainamide and lidocaine. *Eur J Pharmacol*. 1982;81:205-16.
35. Sanfilippo F, et al. Amiodarone or lidocaine for cardiac arrest: a systematic review and meta-analysis. *Resuscitation*. 2016;10:31-7.
36. Foerster K, et al. Prolonged cardiac arrest and resuscitation by extracorporeal life support: favourable outcome without preceding anticoagulation in an experimental setting. *Perfusion*. 2013;28:520-8.
37. Kawase M, et al. Exacerbation of delayed cell injury after transient global ischemia in mutant mice with CuZn superoxide dismutase deficiency. *Stroke*. 1999;30:1962-8.
38. Chan PH. Mitochondria and neuronal death/survival signaling pathways in cerebral ischemia. *Neurochem Res*. 2004;29:1943-9.
39. Suzuki J, Fujimoto S, Mizoi K, Oba M. The protective effect of combined administration of anti-oxidants and perfluorochemicals on cerebral ischemia. *Stroke*. 1984;15:672-9.
40. Kreibich M, et al. Improved outcome in an animal model of prolonged cardiac arrest through pulsatile high pressure controlled automated reperfusion of the whole body: animal model of prolonged CA through pulsatile high pressure CARL. *Artif Organs*. 2018;42:992-1000.
41. Trummer G, et al. Superior neurologic recovery after 15 minutes of normothermic cardiac arrest using an extracorporeal life support system for optimized blood pressure and flow. *Perfusion*. 2014;29:130-8.
42. Foerster K, et al. Twenty minutes of normothermic cardiac arrest in a pig model: the role of short-term hypothermia for neurological outcome. *Perfusion*. 2018;33:270-7.
43. Ehrlich MP, et al. Effect of hypothermia on cerebral blood flow and metabolism in the pig. *Ann Thorac Surg*. 2002;73:191-7.
44. Dankiewicz J, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. *N Engl J Med*. 2021;384:2283-94.
45. Aki M, et al. Mortality in patients with out-of-hospital cardiac arrest undergoing a standardized protocol including therapeutic hypothermia and routine coronary angiography. *JACC Cardiovasc Interv*. 2018;11:1811-20.
46. Tisherman SA, et al. Therapeutic deep hypothermic circulatory arrest in dogs: a resuscitation modality for hemorrhagic shock with 'irreparable' injury. *J Trauma*. 1990;30:836-47.
47. Tisherman SA, et al. Profound hypothermia (less than 10°C) compared with deep hypothermia (15°C) improves neurologic outcome in dogs after two hours' circulatory arrest induced to enable resuscitative surgery. *J Trauma*. 1991;31:1051-61.
48. Alam HB, et al. The rate of induction of hypothermic arrest determines the outcome in a swine model of lethal hemorrhage. *J Trauma Inj Infect Crit Care*. 2004;57:961-9.
49. Erecinska M, Thoresen M, Silver IA. Effects of hypothermia on energy metabolism in mammalian central nervous system. *J Cereb Blood Flow Metab*. 2003;23:513-30.

- 615 50. Pappalardo F, Montisci A. What is extracorporeal cardiopulmonary  
616 resuscitation? *J Thorac Dis.* 2017;9:1415-9.
- 617 51. Nee J, Koerner R, Zickler D, Schroeder T, Enghard P, Nibbe L, et al.  
618 Establishment of an extracorporeal cardio-pulmonary resuscitation program in  
619 Berlin—outcomes of 254 patients with refractory circulatory arrest. *Scand J*  
620 *Trauma Resusc Emerg Med.* 2020;28:96.
- 621 52. Miraglia D, Miguel LA, Alonso W. Extracorporeal cardiopulmonary  
622 resuscitation for in- and out-of-hospital cardiac arrest: systematic review and  
623 meta-analysis of propensity score-matched cohort studies. *J Am Coll Emerg*  
624 *Physicians Open.* 2020;1:342-61.
- 625 53. Inoue A, Hifumi T, Sakamoto T, Kuroda Y. Extracorporeal cardiopulmonary  
626 resuscitation for out-of-hospital cardiac arrest in adult patients. *J Am Heart*  
627 *Assoc.* 2020;9:e015291.
- 628 54. Trummer G, Supady A, Beyersdorf F, Scherer C, Wengenmayer T, Umhau M,  
629 et al. Controlled automated reperfusion of the whole body after 120 minutes of  
630 cardiopulmonary resuscitation: first clinical report. *Scand J Trauma Resusc*  
631 *Emerg Med.* 2017;25:66.
- 632 55. Trummer G, Benk C, Beyersdorf F. Controlled automated reperfusion of the  
633 whole body after cardiac arrest. *J Thorac Dis.* 2019;11:S1464-70.
- 634 56. Pennel T, Beyersdorf F, Gates E, Zilla P. Neurologic recovery after ten minutes of  
635 absent cerebral blood flow at normothermia. *Perfusion.* 2021;36:432-4.

**Key Words:** ECMO, ECLS, controlled automated reperfusion of the whole body, CARL, ischemia reperfusion injury